Weekly Analysts’ Ratings Updates for Progyny (PGNY)

Several analysts have recently updated their ratings and price targets for Progyny (NASDAQ: PGNY):

• 1/21/2026 – Progyny was given a new $35.00 price target on by analysts at JPMorgan Chase & Co..
• 1/21/2026 – Progyny had its “buy” rating reaffirmed by analysts at BTIG Research.
• 1/20/2026 – Progyny was upgraded by analysts at Citigroup Inc. to an “outperform” rating.
• 1/20/2026 – Progyny was upgraded by analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating. They now have a $30.00 price target on the stock.
• 1/8/2026 – Progyny had its price target raised by analysts at KeyCorp from $30.00 to $32.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Progyny was upgraded by analysts at Truist Financial Corporation from a “hold” rating to a “buy” rating. They now have a $34.00 price target on the stock.
• 1/3/2026 – Progyny was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/1/2026 – Progyny was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/29/2025 – Progyny had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Progyny had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Progyny was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/15/2025 – Progyny had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Progyny is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $29.00 price target on the stock.
• 12/8/2025 – Progyny is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $29.00 price target on the stock.

Insiders Place Their Bets

In other news, CEO Peter Anevski acquired 79,500 shares of Progyny stock in a transaction on Thursday, November 13th. The stock was bought at an average cost of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the purchase, the chief executive officer owned 680,251 shares of the company’s stock, valued at $16,523,296.79. This represents a 13.23% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark S. Livingston sold 21,303 shares of Progyny stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares in the company, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 22,046 shares of company stock valued at $561,691 in the last quarter. Insiders own 9.40% of the company’s stock.

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.